文献速递前列腺增生与排尿功能障碍

经会阴间质激光消融术:良性前列腺梗阻微创治疗新选择

Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction.
PubMed 文献 · Eur Urol · 2020-08-28

该前瞻性研究评估了经会阴间质激光消融术(TPLA)治疗良性前列腺梗阻(BPO)的可行性、疗效与安全性。21例前列腺体积<100 ml的男性接受TPLA,术后1、6个月Qmax和IPSS显著改善,射精功能保留,仅1例前列腺脓肿。TPLA是一种微创、有效且安全的BPO治疗选择。

要点

  • TPLA在局部麻醉下经会阴穿刺光纤消融前列腺,术后24小时出院。
  • 术后6个月Qmax改善+4.7 ml/s,IPSS改善-13.1,均具统计学意义。
  • 射精功能保留(MSHQ-EjD提高),仅1例前列腺脓肿并发症。

核心结论

  • TPLA是治疗BPO的微创方法,功能结局和安全性良好,并保留射精功能。

研究设计与样本

  • 前瞻性分析2018年9月至2019年3月因BPO导致LUTS且前列腺体积<100 ml的男性行TPLA的结果。
  • 共21例患者,前列腺体积43.5 ± 8.5 ml,在手术室局部麻醉下使用Soracte Lite-EchoLaserX4系统进行TPLA。

主要发现

  • 所有患者术后24小时内出院,留置经尿道导管8.7 ± 2.5天。
  • 术后1个月,除1例外所有患者停用药物治疗,Qmax显著改善(+3.4 ± 5.7 ml/s;p < 0.01),IPSS显著改善(-5.6 ± 7.0;p < 0.01)。
  • 术后6个月功能结果持续改善,Qmax改善+4.7 ± 6.0 ml/s(p < 0.01),IPSS改善-13.1 ± 4.7(p < 0.01)。
  • 射精功能保留,MSHQ-EjD评分增加(p < 0.05)。
  • 唯一并发症为前列腺脓肿,经会阴引流和抗生素治疗。

临床怎么用

  • 对于前列腺体积<100 ml的BPO患者,TPLA可作为一种微创治疗选择,在局部麻醉下进行,术后恢复快。
  • TPLA可有效改善排尿症状和生活质量,同时保留射精功能,适合关注性功能保留的患者。

局限性

  • 样本量较小(21例),随访时间有限(主要终点6个月,12个月仅电话随访)。
  • 缺乏对照组,非随机设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the algorithm of treatment of benign prostatic obstruction (BPO), the shift from medical therapy to surgery is steep in terms of invasiveness. Recently, a lively interest has developed on alternative micro-invasive options. Transperineal interstitial laser ablation (TPLA) was recently proposed for BPO treatment. OBJECTIVE: This work aims to illustrate feasibility, efficacy and safety profile of TPLA in BPO treatment. DESIGN, SETTING, AND PARTICIPANTS: We prospectively analyzed the results of TPLA performed between September 2018 and March 2019 for LUTS due to BPO, in men with prostate volume <100 ml. SURGICAL PROCEDURE: TPLA was performed in OR, under local anesthesia, using Soracte Lite-EchoLaserX4. Diode laser light is conveyed through 300 μm optical fibers introduced transperineally by 21 Ga needles and placed at a security distance from urethra and bladder neck. EchoLaser Smart Interface eases needle positioning and increases the safety. MEASUREMENTS: The primary endpoint was the variation of Qmax and IPSS at 1, 3 and 6 months. We also assessed the ejaculatory function and recorded complications. These outcomes were further investigated at 12 months by phone call. RESULTS AND LIMITATIONS: 21 men with prostate volume of 43.5 ± 8.5 ml underwent TPLA. All were discharged after 24 h, keeping the transurethral catheter for 8.7 ± 2.5d. At one month all patients but one discontinued medical therapy, showing significant advantage in Qmax (+3.4 ± 5.7 ml/s; p < 0.01) and IPSS (-5.6 ± 7.0; p < 0.01). Functional results were still progressing at 6 months, with Qmax (+4.7 ± 6.0 ml/s; p < 0.01) and IPSS improvement (-13.1 ± 4.7; p < 0.01). The ejaculatory function was preserved as the MSHQ-EjD increased (p < 0.05). The only complication was a prostatic abscess, treated with transperineal drainage and antibiotic. CONCLUSIONS: TPLA is a micro-invasive treatment for BPO showing good functional and safety outcomes. PATIENT SUMMARY: This work illustrates the results of TPLA to treat LUTS due to BPO, showing high efficacy, preservation of the ejaculation, and low complication rate.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. de Rienzo G, Lorusso A, Minafra P, et al. Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol. 2020. PMID: 32868137. doi:10.1016/j.eururo.2020.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。